Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Aclaris Therapeutics ( (ACRS) ) just unveiled an update.
On July 29, 2025, Aclaris Therapeutics announced the top-line results of their Phase 2a clinical trial for ATI-2138, an investigational oral covalent ITK/JAK3 inhibitor, in subjects with moderate to severe atopic dermatitis. The trial showed that ATI-2138 was well tolerated with no severe adverse events, and demonstrated significant efficacy, with a mean improvement in Eczema Area and Severity Score (EASI) of 77% over 12 weeks, excluding outliers. This development could enhance Aclaris’ positioning in the treatment of immuno-inflammatory diseases, offering a promising therapeutic option for patients and potentially impacting future market strategies.
The most recent analyst rating on (ACRS) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Aclaris Therapeutics stock, see the ACRS Stock Forecast page.
Spark’s Take on ACRS Stock
According to Spark, TipRanks’ AI Analyst, ACRS is a Neutral.
Aclaris Therapeutics is currently facing significant challenges, with a primary focus on its financial performance. The company’s lack of profitability and reliance on external financing are major concerns. The technical analysis further underscores negative momentum, although oversold indicators might suggest a potential short-term rebound. Valuation is unattractive due to negative earnings, and no significant earnings call data or corporate events are available to offset these issues.
To see Spark’s full report on ACRS stock, click here.
More about Aclaris Therapeutics
Aclaris Therapeutics, Inc. operates in the biopharmaceutical industry, focusing on developing innovative therapies for immuno-inflammatory diseases. Their primary products include investigational oral covalent ITK/JAK3 inhibitors, with a market focus on conditions such as atopic dermatitis and potentially alopecia areata.
Average Trading Volume: 897,880
Technical Sentiment Signal: Hold
Current Market Cap: $181.9M
Learn more about ACRS stock on TipRanks’ Stock Analysis page.